Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10596818
Filing Date		2006-06-26
First Named Inventor	Hikar	u Matsuda
Art Unit		TBA
Examiner Name	TBA	
Attorney Docket Number		49288 3000

				LX	iiioi ita	iiie	IUA					
				Attorn	ey Doc	ket Numbe	er	49288.3000				
					U.S.	PATENTS				Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of I		tee or Applicant ent	Releva		Lines where ges or Relev	
	1											
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click	the A	dd button.		Add		
			U.S.P	ATENT	APPLI	CATION P	UBLI	CATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Kind Publication Name of Patentee of cited Document			Releva		Lines where ges or Relev			
	1											
If you wis	h to a	dd additional U.S. Publi	ished Ap	plication	citatio	n informatio	on ple	ase click the Ad	d button	1. Add		
				FOREIG	GN PAT	TENT DOC	UME	NTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publicatio Date	n	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	+=
	1	09-122227	JP			1997-05-1	3	Bio Eng Lab KK				
	2	2003-190192	JP			2003-07-0	8	Japan Science & Technology Corp Champion KK				С
							- 1	Champion KK				
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	informatio			button	Add		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10596818
Filing Date		2006-06-26
First Named Inventor	Hikar	u Matsuda
Art Unit		TBA
Examiner Name	TBA	
Attorney Docket Number		49288.3000

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	UCHIMURA, E., et al., "Novel Method of Preparing Acellular Cardiovascular Grafts by Decellularization With Poly (Ethylene Glyco)", Journal of Biomedical Materials Research, Part A, October 2003, Vol. 67A, No. 3, p. 834-837	
	2	UEDA, Y., et al., "Development of Acellular Tissue for Cardiovascular Applications", International Journal of Artificial Organs, July 2003, Volume 26, Number 7, p. 598	
	3	"Fibronectin-HGF, In Situ", The Japanese Journal of Thoracic and Cardiovascular Surgery, Vol. 51, October 2003, p. 220	
	4	Copy of International Search Report dated 04/26/2005	
If you wish	to a	id additional non-patent literature document citation information please click the Add button Add	_

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard St.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10596818	
Filing Date		2006-06-26	
First Named Inventor	Hikaru Matsuda		
Art Unit		TBA	
Examiner Name	TBA		
Attorney Docket Number		49288.3000	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.98 to make the appropriate selection(s):
---------------	--------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

OR

That no item of Information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person spinifip the certification after making reasonable inquiry, no tern of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 27 CFR 1.57(e)(2).

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Howard I Sobelman/	Date (YYYY-MM-DD)	2006-07-13
Name/Print	Howard I Sobelman	Registration Number	39038

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examines your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission of the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet for disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via fifed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.